comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Free Comparison Chart: GIP/GLP-1 Receptor for Type 2 Diabetes 🔗 Link in bio #FOAMed #Type2Diabetes #GLP1 comparing cardiovascular and kidney outcomes

Colhoun HM, Lingvay I, Brown PM, et al

Secondary endpoints were univariately compared between the GLP-1-RA and UCWM groups

World J Hepatol

Consistent with these effects, GLP-1 RAs have been associated with substantial weight loss in clinical trials, leading to FDA approval of two of these agents liraglutide and semaglutide for chronic weight management in adults with obesity or with overweight and at least one weight-related comorbidity

Decreased mortality, anti-inflammatory properties and neuroprotective effects can be beneficial in chronic substance use which is associated with neuroinflammation and oxidative stress

99: 15901595 [DOI] [PubMed] [Google Scholar] 142.Ding KH, Zhong Q, Xie D, et al